Related Experiment Video

Updated: Dec 12, 2025

Spatial and Temporal Control of Murine Melanoma Initiation from Mutant Melanocyte Stem Cells
06:09

Spatial and Temporal Control of Murine Melanoma Initiation from Mutant Melanocyte Stem Cells

Published on: June 7, 2019

9.3K

Current State of Target Treatment in BRAF Mutated Melanoma

Enrica Teresa Tanda1, Irene Vanni2,3, Andrea Boutros1

  • 1Medical Oncology, IRCCS Ospedale Policlinico San Martino, Genoa, Italy.

Frontiers in Molecular Biosciences
|August 8, 2020
PubMed

Insights

Targeted BRAF inhibitors have revolutionized advanced melanoma treatment, significantly improving patient survival. This review details their development, current use, resistance, and future directions for BRAF-mutated melanoma.

Area of Science:

  • Oncology
  • Molecular Biology
  • Dermatology

Background:

  • Melanoma incidence is rising, with significant mortality despite advances.
  • Systemic therapies before 2011 offered limited survival benefits for advanced melanoma.
  • Chemotherapy was the standard of care with poor outcomes.

Purpose of the Study:

  • To review the evolution of molecular-targeted therapies for BRAF-mutated melanoma.
  • To outline the current therapeutic landscape for BRAF-mutated melanoma.
  • To discuss resistance mechanisms and future perspectives.

Main Methods:

  • Literature review of studies on BRAF inhibitors in melanoma.
  • Analysis of clinical trial data and treatment guidelines.
  • Synthesis of information on resistance and future therapeutic strategies.

Main Results:

  • BRAF V600 mutation identification led to targeted BRAF inhibitors.
  • BRAF inhibitors have dramatically improved outcomes in advanced melanoma.
  • Understanding resistance mechanisms is crucial for further progress.

Conclusions:

  • BRAF inhibitors represent a paradigm shift in advanced melanoma treatment.
  • Ongoing research focuses on overcoming resistance and improving long-term survival.
  • Future strategies involve combination therapies and novel drug development.
Keywords:
BRAF mutationMAPK pathwaymelanomametastatic diseasetargeted therapy

More Related Videos

Analysis of Lymph Node Volume by Ultra-High-Frequency Ultrasound Imaging in the Braf/Pten Genetically Engineered Mouse Model of Melanoma08:18

Analysis of Lymph Node Volume by Ultra-High-Frequency Ultrasound Imaging in the Braf/Pten Genetically Engineered Mouse Model of Melanoma

Published on: September 8, 2021

3.2K
A 3D Organotypic Melanoma Spheroid Skin Model08:49

A 3D Organotypic Melanoma Spheroid Skin Model

Published on: May 18, 2018

16.3K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.5K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.7K
Skin Cancer01:30

Skin Cancer

Skin cancer is a type of cancer that occurs when there is an abnormal growth of skin cells, usually triggered by damage to the DNA within the skin cells. It is primarily caused by exposure to ultraviolet (UV) radiation from the sun or artificial sources like tanning beds. Skin cancer is the most common type of cancer worldwide, and its incidence continues to rise.
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...
5.6K
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.5K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.5K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
7.5K